Soluble interleukin-6 receptor activates the human papillomavirus type 18 long control region in SW756 cervical carcinoma cells in a STAT3-dependent manner Free

Abstract

Cervical carcinoma cells producing high levels of interleukin-6 (IL-6) were shown to be unresponsive to the cytokine IL-6 due to the loss of their IL-6 receptor. Addition of IL-6 receptor in a soluble form restores IL-6 signalling in SW756 carcinoma cells. This leads to a rapid and strong activation of the transcription factor signal transducer and activator of transcription 3 (STAT3). Nuclear factor IL-6 (NF-IL6, C/EBPβ) was induced only as a late event. While C/EBPβ significantly repressed the human papillomavirus type 18 long control region (HPV18-LCR), IL-6 signalling unexpectedly activated the HPV18-LCR in these cells. This IL-6 receptor-mediated induction could be completely reverted by transfection of a dominant-negative STAT3 but not STAT1 expression construct, indicating that STAT3 might play an important role in HPV18 oncogene promoter activation.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-82-10-2335
2001-10-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/82/10/0822335a.html?itemId=/content/journal/jgv/10.1099/0022-1317-82-10-2335&mimeType=html&fmt=ahah

References

  1. Akira S., Isshiki H., Sugita T., Tanabe O., Kinoshita S., Nishio Y., Nakajima T., Hirano T., Kishimoto T. 1990; A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO Journal 9:1897–1906
    [Google Scholar]
  2. Altenburg A., Baldus S. E., Smola H., Pfister H., Hess S. 1999; CD40 ligand–CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. Journal of Immunology 162:4140–4147
    [Google Scholar]
  3. Bauknecht T., See R. H., Shi Y. 1996; A novel C/EBP beta–YY1 complex controls the cell-type-specific activity of the human papillomavirus type 18 upstream regulatory region. Journal of Virology 70:7695–7705
    [Google Scholar]
  4. Bauknecht T., Randelzhofer B., Schmitt B., Ban Z., Hernando J. J., Bauknecht T. 1999; Response to IL-6 of HPV-18 cervical carcinoma cell lines. Virology 258:344–354
    [Google Scholar]
  5. Baumann H., Morella K. K., Campos S. P., Cao Z., Jahreis G. P. 1992; Role of CAAT-enhancer binding protein isoforms in the cytokine regulation of acute-phase plasma protein genes. Journal of Biological Chemistry 267:19744–19751
    [Google Scholar]
  6. Boulton T. G., Stahl N., Yancopoulos G. D. 1994; Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. Journal of Biological Chemistry 269:11648–11655
    [Google Scholar]
  7. Chen L., Mory Y., Zilberstein A., Revel M. 1988; Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proceedings of the National Academy of Sciences, USA 85:8037–8041
    [Google Scholar]
  8. Daeipour M., Kumar G., Amaral M. C., Nel A. E. 1993; Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF-10. Journal of Immunology 150:4743–4753
    [Google Scholar]
  9. Eustace D., Han X., Gooding R., Rowbottom A., Riches P., Heyderman E. 1993; Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecologic Oncology 50:15–19
    [Google Scholar]
  10. Heinrich P. C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. 1998; Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochemistry Journal 334:297–314
    [Google Scholar]
  11. Hess S., Smola H., Sandaradura De Silva U., Hadaschik D., Kube D., Baldus S. E., Flucke U., Pfister H. 2000; Loss of IL-6 receptor expression in cervical carcinoma cells inhibits autocrine IL-6 stimulation: abrogation of constitutive monocyte chemoattractant protein-1 production. Journal of Immunology 165:1939–1948
    [Google Scholar]
  12. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. 1990; Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149–1157
    [Google Scholar]
  13. Hirano T., Nakajima K., Hibi M. 1997; Signaling mechanisms through gp130: a model of the cytokine system. Cytokine & Growth Factor Reviews 8:241–252
    [Google Scholar]
  14. Hirano T., Ishihara K., Hibi M. 2000; Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19:2548–2556
    [Google Scholar]
  15. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. and others 1988; Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85
    [Google Scholar]
  16. Klein B., Zhang X. G., Lu Z. Y., Bataille R. 1995; Interleukin-6 in human multiple myeloma. Blood 85:863–872
    [Google Scholar]
  17. Kyo S., Inoue M., Nishio Y., Nakanishi K., Akira S., Inoue H., Yutsudo M., Tanizawa O., Hakura A. 1993; NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region. Journal of Virology 67:1058–1066
    [Google Scholar]
  18. Lutticken C., Wegenka U. M., Yuan J., Buschmann J., Schindler C., Ziemiecki A., Harpur A. G., Wilks A. F., Yasukawa K., Taga T. and others 1994; Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263:89–92
    [Google Scholar]
  19. Malejczyk J., Malejczyk M., Urbanski A., Kock A., Jablonska S., Orth G., Luger T. A. 1991; Constitutive release of IL6 by human papillomavirus type 16 (HPV16)-harboring keratinocytes: a mechanism augmenting the NK-cell-mediated lysis of HPV-bearing neoplastic cells. Cellular Immunology 136:155–164
    [Google Scholar]
  20. Morinaga Y., Suzuki H., Takatsuki F., Akiyama Y., Taniyama T., Matsushima K., Onozaki K. 1989; Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines. Journal of Immunology 143:3538–3542
    [Google Scholar]
  21. Murakami M., Hibi M., Nakagawa N., Nakagawa T., Yasukawa K., Yamanishi K., Taga T., Kishimoto T. 1993; IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808–1810
    [Google Scholar]
  22. Nakajima K., Yamanaka Y., Nakae K., Kojima H., Ichiba M., Kiuchi N., Kitaoka T., Fukada T., Hibi M., Hirano T. 1996; A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO Journal 15:3651–3658
    [Google Scholar]
  23. Niehof M., Streetz K., Rakemann T., Bischoff S. C., Manns M. P., Horn F., Trautwein C. 2000; Interleukin-6-induced tethering of STAT3 to the LAP/C/EBPbeta promoter suggests a new mechanism of transcriptional regulation by STAT3. Journal of Biological Chemistry 276:9016–9027
    [Google Scholar]
  24. Rakemann T., Niehof M., Kubicka S., Fischer M., Manns M. P., Rose-John S., Trautwein C. 1999; The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. Journal of Biological Chemistry 274:1257–1266
    [Google Scholar]
  25. Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., Faggioni R., Luini W., van Hinsbergh V., Sozzani S., Bussolino F., Poli V., Ciliberto G., Mantovani A. 1997; Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315–325
    [Google Scholar]
  26. Schaefer T. S., Sanders L. K., Nathans D. 1995; Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proceedings of the National Academy of Sciences, USA 92:9097–9101
    [Google Scholar]
  27. Schreiber E., Matthias P., Muller M. M., Schaffner W. 1989; Rapid detection of octamer binding proteins with ‘mini-extracts’, prepared from a small number of cells. Nucleic Acids Research 17:6419
    [Google Scholar]
  28. Stahl N., Boulton T. G., Farruggella T., Ip N. Y., Davis S., Witthuhn B. A., Quelle F. W., Silvennoinen O., Barbieri G., Pellegrini S. and others 1994; Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263:92–95
    [Google Scholar]
  29. Steger G., Corbach S. 1997; Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. Journal of Virology 71:50–58
    [Google Scholar]
  30. Struyk L., van der Meijden E., Minnaar R., Fontaine V., Meijer I., ter Schegget J. 2000; Transcriptional regulation of human papillomavirus type 16 LCR by different C/EBPbeta isoforms. Molecular Carcinogenesis 28:42–50
    [Google Scholar]
  31. Taga T., Kishimoto T. 1997; Gp130 and the interleukin-6 family of cytokines. Annual Review of Immunology 15:797–819
    [Google Scholar]
  32. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. 1989; Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–581
    [Google Scholar]
  33. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T. and others 1993; Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proceedings of the National Academy of Sciences, USA 90:11924–11928
    [Google Scholar]
  34. Zhong Z., Wen Z., Darnell J.E. Jr 1994; Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95–98
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-82-10-2335
Loading
/content/journal/jgv/10.1099/0022-1317-82-10-2335
Loading

Data & Media loading...

Most cited Most Cited RSS feed